Mammalian genomes are populated with thousands of transcriptional enhancers that orchestrate cell-type-specific gene expression programs [1] [2] [3] [4] , but how those enhancers are exploited to institute alternative, signal-dependent transcriptional responses remains poorly understood. Here we present evidence that cell-lineagespecific factors, such as FoxA1, can simultaneously facilitate and restrict key regulated transcription factors, exemplified by the androgen receptor (AR), to act on structurally and functionally distinct classes of enhancer. Consequently, FoxA1 downregulation, an unfavourable prognostic sign in certain advanced prostate tumours, triggers dramatic reprogramming of the hormonal response by causing a massive switch in AR binding to a distinct cohort of pre-established enhancers. These enhancers are functional, as evidenced by the production of enhancer-templated non-coding RNA (eRNA 5 ) based on global nuclear run-on sequencing (GRO-seq) analysis 6 , with a unique class apparently requiring no nucleosome remodelling to induce specific enhancer-promoter looping and gene activation. GRO-seq data also suggest that liganded AR induces both transcription initiation and elongation. Together, these findings reveal a large repository of active enhancers that can be dynamically tuned to elicit alternative gene expression programs, which may underlie many sequential gene expression events in development, cell differentiation and disease progression.
The wide diversity of mammalian cells is determined by a large repertoire of constitutive and inducible genes, which are regulated by general and cell-type-specific transcription factors and cofactors through regulatory genomic elements 7, 8 . Recent studies reveal that gene promoters are marked by tri-methylated H3K4 (H3K4me3) and distal regulatory elements are often associated with mono-methylated H3K4 (H3K4me1) 1, 2 . Because these H3K4me1-positive, H3K4me3-negative regions exhibit striking cell-type specificity 1,2 , we used this signature to characterize potential enhancers in prostatic LNCaP cells in which one of key regulatory transcriptional programs is mediated by the AR. We identified by chromatin immunoprecipitation (ChIP)-sequencing 14,283 H3K4me3-marked and 51,544 H3K4me1-marked loci in androgen (5a-dihydrotestosterone, (DHT))-treated LNCaP cells, among which 43,565 loci are uniquely marked by H3K4me1, largely localized distal to annotated transcriptional start sites (TSSs) (94%), and associated with other marks linked to enhancer activities (Fig. 1a) .
De novo DNA motif analysis revealed several highly enriched motifs, particularly the forkhead motif ( Fig. 1b) . Using a specific antibody against FoxA1, a major FOX family member expressed in LNCaP cells and normal prostate gland [9] [10] [11] ( Supplementary Fig. 1 ), we identified 33,426 FoxA1-bound sites, which extensively overlap with distal H3K4me1-marked regions ( Fig. 1c and Supplementary Fig. 2a ; see on KLK3 enhancer 12 in Supplementary Fig. 2b ). RNA profiling supports the functional relevance of these FoxA1/H3K4me1 loci, as genes responsive to FOXA1 short interfering RNA (siRNA) are located more proximally to FoxA1/H3K4me1-marked loci than non-responsive genes ( Fig. 1d and Supplementary Fig. 3 ).
FoxA1 has been characterized as a 'pioneer' factor to facilitate DNA binding by other sequence-specific transcription factors 9, [13] [14] [15] [16] and 'translate' H3K4me1/me2 into AR-mediated gene expression 9 . Comparing the profile of H3K4me1 and H3K27ac before and after FOXA1 knockdown, we detected three classes of FoxA1-binding sites based on the H3K4me1 signal exhibiting reduced (,22%), relatively unaffected (,74%) or even increased (,3.4%) levels over candidate enhancers ( Fig. 1e-g and Supplementary Fig. 4 ). RNA profiling analysis agrees with the functional significance of these selective FoxA1 effects, revealing more downregulated genes in the first class, roughly equal numbers of up-or downregulated genes in the second and more upregulated genes in the third ( Fig. 1h ), suggesting a contribution of FoxA1 to 'writing' and 'reading' the 'histone code' on different enhancer cohorts, in line with its critical function in prostate gland development 10, 11 .
The rationale for our experimental strategy to use RNA interference (RNAi) to study FoxA1-regulated enhancer network is the association of decreased FOXA1 expression with castration-resistant, poor prognostic prostate tumours ( Supplementary Fig. 5 ). In LNCaP cells, FOXA1 RNAi enhanced cell entrance to S phase with reduced hormone ( Fig. 2a ). To understand the mechanistic basis for elevated hormone responsiveness, we mapped AR-binding sites, identifying 3,115 high confident loci with approximately 65% co-incident with H3K4me1. De novo motif analysis revealed highly enriched elements for both AR and FoxA1, including a composite motif consisting of a FOX motif and AR regulatory element (ARE) half site, suggesting ternary complex formation on these sites ( Fig. 2b) . Indeed, 1,684 AR-bound loci (54% of total) are co-occupied by FoxA1 in DHT-treated LNCaP cells and FoxA1 appears to bind to most of these sites (,70%) before hormone treatment ( Supplementary Fig. 6 ).
The conundrum is that, although FoxA1 is known to facilitate AR binding on several DHT-responsive genes 9 , FOXA1 RNAi actually markedly elevated, rather than diminished, the DHT response ( Fig. 2a ). We found that approximately 60% of the original AR binding events were 'expectedly' lost in response to FOXA1 RNAi, which we refer to as the 'lost' AR program ( Fig. 2c, d) . We refer to the remaining approximate 40% of AR binding events as the 'conserved' AR program, which often exhibited enhanced AR binding. Strikingly, we detected a massive gain of 10,869 new AR binding loci, referred to as the 'gained' AR program ( Fig. 2c, d ). We extensively validated each of these AR programs by conventional ChIP-quantitative PCR (qPCR) ( Fig. 2e ). This induced AR reprogramming appears to be qualitatively and quantitatively distinct from reported AR re-targeting on androgenresistant LNCaP-abl cells compared with parental LNCaP cells 17 and is in sharp contrast to FoxA1-dependent genomic targeting of the oestrogen receptor-a (ER-a) in breast cancer MCF7 cells 18 . In concert with such massive AR reprogramming, we observed corresponding changes in gene expression in each of three AR programs ( Fig. 2f , g and Supplementary Fig. 7 ). The newly induced AR expression program is also linked to AR binding events ( Fig. 2h ), suggesting a direct gain-offunction on DHT-responsive genes, as illustrated on SOX9 and other genes ( Supplementary Fig. 8 ), which have been previously documented to play critical roles in cancer progression 19, 20 . Because we also observed an approximate threefold elevation of AR expression in FOXA1 RNAi-treated cells ( Supplementary Fig. 9a ), we tested the possibility that increased AR expression might trigger these effects. We found that AR overexpression alone was insufficient to induce AR reprogramming ( Supplementary Fig. 9b ).
To explore the mechanism for AR reprogramming, we determined FoxA1 binding on different AR programs. We found that the gained AR program is largely devoid of FoxA1, whereas FoxA1 is present in more than half of the lost and conserved AR programs ( Supplementary  Fig. 10 ). This raises the possibility that FoxA1 may facilitate AR binding to its original binding program, but trans-repress AR from binding to other genomic regions that lack FoxA1-binding sites in the gained program, a strategy frequently used by other transcription activators 21 . Relative numbers of propidium-iodide-labelled cells in S-phase at different DHT concentrations were determined by FASCan. The P value for the difference detected at each hormonal level is indicated; mean 6 s.e.m. is based on four independent experiments. b, Top-enriched motifs associated with AR-occupied loci (n 5 3,115). c, Comparison between genome-wide AR binding programs before and after FOXA1 knockdown in DHT-treated LNCaP cells. d, Quantitative levels of AR binding in the 'lost', 'conserved' and 'gained' programs. Outliers were omitted from box plots. e, ChIP-qPCR-validated AR binding events on randomly selected loci from the lost (n 5 22), conserved (n 5 27) and gained (n 5 16) programs. f, Microarray analysis of DHT-induced genes before and after FOXA1 knockdown. g, Quantitative analysis of gained androgen upregulated genes based on microarray analysis in f. Outliers were omitted from box plots. h, Genomic distance of androgen-responsive genes from TSS to the nearest AR-binding site in the original and gained AR-binding programs. a, Distribution of histone marks within 62-kb windows around distinct genomic regions (n 5 43,565) marked by H3K4me1, but not H3K4me3, in androgen (DHT)-stimulated LNCaP cells. The ChIP-seq data sets for H3K4me1, H3K4me2, H3K4me3, H3K27ac, H4K5ac and p300 were each aligned with respect to the centre of the H3K4me1 signal and sorted by the length of H3K4me1-marked regions. b, Top-enriched DNA motifs with significant P values and prospective families of DNA binding transcription factors identified by de novo motif analysis of non-promoter regions marked by H3K4me1. c, Percentage of H3K4me1-marked regions that show FoxA1 binding events (top panel) and percentage of FoxA1-binding sites that are marked by H3K4me1 (bottom panel). Note that H3K4me1-marked regions tend to be broad, but FoxA1-binding sites are discrete; as a result, many H3K4me1-positive regions may contain more than one FoxA1-binding site. d, Genomic distance from FoxA1/H3K4me1-positive loci to the nearest TSS of genes in response to FOXA1 knockdown. Outliers were omitted from box plots. P values indicate the significance in pair-wise comparisons. e-g, Three classes of FoxA1/H3K4me1-positive loci according to the response in levels of H3K4me1 to FOXA1 knockdown: greater than 1.5-fold decrease (e), no significant change (f) and greater than 1.5-fold increase (g). h, Ratio (log 2 ) of up-and downregulated genes in each H3K4me1-responsive category in e-g. CTL, control.
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Indeed, as previously reported 22 , FoxA1 overexpression squelched ARE-driven transcription in transfected HEK293 cells (Supplementary Fig. 11 ), which is consistent with the ability of AR to interact with FoxA1 directly 23 . This mechanism appears to be exploited during tumour progression because an AR mutation identified in advanced prostate tumours lacks part of the hinge domain important for interactions with FoxA1, its ability to interact with FoxA1, and became resistant to FoxA1-mediated trans-repression ( Supplementary Fig.  11b , c). Furthermore, our functional analysis indicates that the missing AR ligand-binding domain also contributes to AR:FoxA1 interactions ( Supplementary Fig. 12 ). Interestingly, similar AR truncations have also been reported to result from alternative splicing, gene rearrangement and/or calpain-mediated cleavage ( Supplementary Fig. 13 ). Based on these findings, we propose that FoxA1 regulates AR genomic targeting by simultaneously anchoring AR to cognate loci and restricting AR from other ARE-containing loci in the human genome.
To understand how reprogrammed AR binding is translated to altered hormonal response, we took advantage of the recently established GRO-seq 6 to detect the functional relationship between AR binding and hormone-induced gene expression. This powerful genome-wide interrogation of ongoing transcription detected a broad scope of nascent RNAs. We uncovered 28,318 transcripts with 15,656 annotated and 12,662 unannotated transcripts, among which 450 coding and 347 unannotated transcripts were induced more than 1.5-fold with even just 1 h DHT treatment ( Supplementary Fig. 14) . The TSSs of GRO-seq defined transcripts are typically marked by H3K4me3 and H3K27ac ( Supplementary Fig. 15a, b ). Importantly, GRO-seq also detected non-coding RNAs from a subset of H3K4me1-positive, H3K4me3-negative regions ( Supplementary Fig. 15c ). As illustrated on the enhancer of the KLK3 transcription unit ( Fig. 3a ), these eRNAs are largely symmetrical and bidirectional (see additional examples on other well-known hormone regulated genes, such as PMEPA1 and KLK2 in Supplementary Fig. 16 ). Interestingly, we often detected a large amount of nascent RNA before DHT treatment, particularly near their TSSs (for example, KLK3); DHT not only enhanced the expression of these nascent RNAs, but also allowed the extension of transcription towards the end of the gene ( Fig. 3a and Supplementary Fig.  16 ). We estimated that approximately 79% of the transcription units induced by liganded AR are regulated at the level of transcriptional initiation, whereas approximately 21% appear to be primarily regulated at the level of elongation ( Supplementary Fig. 17 ).
The ability to detect regulated eRNA expression allowed us to analyse different AR programs during transcriptional reprogramming. In the presence of FoxA1, DHT enhanced eRNA expression from ARbound enhancers in both the lost and conserved AR programs. In contrast, a basal level of eRNAs was detectable on the gained program, but was independent of the hormone treatment, indicating that these are pre-established enhancers (Fig. 3b ). In response to 
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the expression of eRNAs was diminished from the lost program, but modestly or dramatically enhanced from the conserved and gained programs, respectively (Fig. 3c) . The DHT-induced nascent transcripts (detected by GRO-seq) and steady-state RNAs (detected by microarrays) best predict direct target genes by liganded AR, as they show the shortest distance (,50 kilobases (kb)) to nearby AR-binding sites compared with genes identified by either criterion alone (Supplementary Fig. 18 ), indicating that AR-activated enhancers marked by increased eRNA are responsible for activation of nearby coding transcription units.
In concert with differential eRNA expression, we also observed corresponding changes in levels of another mark in the final step of enhancer activation 4 , specifically p300, on both conserved and gained AR programs (Fig. 3d ). Interestingly, enhancers in the lost AR program continued to exhibit significant p300 binding, even after AR binding and eRNA expression were diminished in FOXA1 knockdown cells (Fig. 3c, d) . The transcription mediator Med12 has recently been suggested to mediate enhancer-promoter looping 24 . We tested Med12 binding on individual AR programs, finding that it exhibited an identical binding pattern to p300 (Fig. 3e ). Enhanced Med12 binding on the conserved and gained programs after FOXA1 knockdown suggests elevated or newly activated enhancer-promoter interactions. This was demonstrated by the 3C assay on two representative genes where FOXA1 knockdown either enhanced (on the FASN locus from the conserved AR program) or create new (on the NDRG1 locus in the gained AR program) long-range interactions between AR-bound enhancers and specific gene promoters in DHT-treated cells (Fig. 3f,   g and Supplementary Fig. 19 ). These data strongly suggest that the induction of eRNAs, rather than binding of either p300 or Med12, is the most precise mark of the final, functional looping between an activated enhancer and its regulated gene promoter.
Addressing the structural basis for different functional classes of AR enhancers, we note that the distinct profiles of H3K4me1 and H3K27ac on the lost, conserved and gained AR programs and FOXA1 RNAi had little effect on these profiles (Fig. 4a, b and Supplementary Fig. 20) . The histone marks H3K4me1 and H3K27ac around the lost and conserved AR programs exhibit a bimodal distribution, which is particularly pronounced on the lost program (Fig. 4a, bottom panel) . The DNAbinding sites in the lost AR program are actually significantly less enriched in canonical AREs, which may render AR binding on these sites particularly dependent on FoxA1, whereas both the conserved and gained AR programs are associated with nearly perfect palindromic, canonical AREs ( Supplementary Fig. 21 ), explaining why AR is able to target those sites in a FoxA1-independent manner. Strikingly, the gained AR-binding sites are coincident with sharp H3K4me1 and H3K27ac peaks (Fig. 4a, b , middle panels), suggesting a distinct nucleosome architecture underlying the gained AR program.
A recent study has suggested that AR binding leads to dynamic dismissal of a central, H2A.Z-containing nucleosome, being replaced by two flanking H3K4me2-marked nucleosomes 25 . We found that the lost AR program was largely devoid of a 'central' nucleosome even before AR binding (Fig. 4c, bottom bind to ARE in relatively nucleosome-free regions. AR binding does not induce nucleosome remodelling in this class of enhancers. In class II (the conserved AR program), AR binds independently of FoxA1 to ARE, inducing nucleosome remodelling. In class III (the gained AR program), FoxA1 restricts AR binding, despite the presence of strong AREs. Although pre-established, these gained loci exhibit a strong central nucleosomes and are associated with H2A.Z, which is not affected by AR binding. FOXA1 knockdown converted these sites to androgen-responsive sites. In all these three classes, eRNAs were generated or increased after AR binding. e:p, enhancer:promoter.
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is largely independent of FoxA1 ( Fig. 4c, d, top panels) . The gained program showed a strong H3K4me2-marked central nucleosome both before and after AR binding ( Fig. 4c, d, middle panel) . Thus, this gained AR program represents a new type of enhancer topography that requires no nucleosome remodelling for enhancer recognition and subsequent enhancer-promoter interactions. H2A.Z is prevalently associated with the gained AR program, modestly with the conserved AR program and absent in the lost AR program (Fig. 4e ). Together, these findings establish distinct chromatin structures underlying functionally distinct classes of AR enhancer.
In summary, our findings imply a general principle for establishing cell-type-specific transcription programs. Cell-lineage-specific factors (such as FoxA1) coupled with other general transcriptional factors 'create' a cell-type-specific enhancer network, allowing other regulated factors (such as AR) to 'activate' these pre-established enhancers (Fig. 4f ). The enhancer activation process is tightly linked to eRNA production, which appear to serve as a more robust indicator of enhancer activities than any enhancer-bound transcription activators or chromatin marks. On the current biology model, AR reprogramming dramatically altered the androgen-responsive pathway, which, according to GO analysis ( Supplementary Fig. 22 and Fig. 23 ), may contribute to enhanced cell growth and the establishment of an appropriate microenvironment in advanced prostate cancer [26] [27] [28] . Together, these findings provide a conceptual framework to understand complex gene-expression switching events, as occurs during disease progression and development.
METHODS SUMMARY
Experiments were performed on LNCaP cells, LNCaP-AR cells (gift of C. Sawyers) and HEK293 cells. ChIPs were done as previously described 29 and GRO was performed as described 6, 30 . Control siRNA was purchased from Qiagen (1027280). FOXA1 siRNA 1 (M-010319) and 2 (sense 59-GAGAGAAAAAAUCAACAGC-39; antisense 59-GCUGUUGAUUUUUUCUCUC-39) 9 were purchased from or synthesized by Dharmacon.
METHODS
Antibodies. Specific antibodies were purchased from the following commercial sources: anti-FoxA1 (ab5089), anti-H3K4me1 (ab8899), anti-H3K27ac (ab4729), anti-H3K36me3 (ab9050) and H2A.Z (ab4174) from Abcam; anti-AR (N-20), anti-FoxA1 (C-20) and p300 (C-20, gift of B. Ren) from Santa Cruz Biotechnology; anti-H3K4me2 (07-030), anti-H3K4me3 (07-473), anti-H4K5ac (07-327) and anti-H3K27me3 (07-449) from Upstate Biotechnology; anti-Med12 (A300-774A) from Bethyl Laboratories; and anti-beta Actin (AC74) from Sigma. siRNA transfection. One day before transfection, LNCaP cells were seeded in RPMI 1640 medium with 10% FBS. Six hours after siRNA transfection (20 pmol ml 21 ) with Lipofectamine 2000 (Invitrogen), cells were washed twice with PBS and then maintained in hormone-deprived phenol-free RPMI 1640 media. For gene expression profiling and western blotting, cells were cultured for 3 days after transfection and then treated with DHT for 20 h; for ChIP-qPCR and ChIP-seq, cells were cultured for 4 days after transfection and then treated with DHT for 1 h. ChIP-seq analysis at the nucleosome resolution was based on cells treated with DHT for 4 h. 3C assay. Cells were crosslinked with 1% formaldehyde for 20 min at room temperature and processed according to the standard 3C protocol 31 . For the study on the FASN locus, fixed chromatin from 5 3 10 6 cells was digested with 400 units of BglII and EcoR I (NEB). For the NDRG1 locus, fixed chromatin from 5 3 10 6 cells was digested with 400 units of HindIII (NEB). Ligation was done with 800 units of T4 DNA ligase (NEB) for 4 h. The 3C product was quantified by qPCR after diluting the template tenfold compared with purified genomic DNA of known concentration. For each semi-quantitative PCR, the amount of template was titrated to determine the linear range in which the PCR product was amplified. PCR primers were designed next to BglII and HindIII restriction sites, respectively, for the FASN (all in minus strand) promoter (59-AAGCTGTGAGTCAGCAT GGTAG-39) and three upstream sites (238kb, 59-TGTCTTCTGATGTGTCTG CTTAGAG-39; 245kb, 59-AATCCTGCTCAGGAATCTGTATGT-39; 254kb, 59-GGACACTACTGCTTTTTCCTGTG-39) and for the NDRG1 (all in plus strand) promoter (59-ATAGGTTCTGCCTTATTAGGG-39) and three upstream sties (242kb, 59-ATAGAGTTAGAGAAACGGAGGCAGT-39; 256kb: 59-GCC GTGAAGAATAAACAAGATGAG-39; 262kb: 59-ACACATTTTGTTCCCAG TGCAG-39). Co-IP and western blotting analysis. HEK293 cells were seeded for 1 day, transfected with the expression plasmids expressing wild-type, mutant AR and FoxA1 using Lipofectamine2000 (Invitrogen) and then changed to hormone-depleted, phenol-free DMEM medium. One day after plasmid transfection, cells were treated with 100 nM DHT for another day. Cells were washed by cold PBS twice and treated with 1 ml of lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40) supplemented with a cocktail of proteinase inhibitors (Sigma) for 5 min at 4 uC. Lysed cells were collected, rotated for 1 h at 4 uC and cell debris removed by centrifugation at 18,000g for 30 min in a cold room. The supernatant was incubated with anti-AR, anti-FoxA1 or immunoglobulin-G overnight at 4 uC followed by the addition of 50 ml of 50% protein G beads to each tube. After rotating for another 2 h at 4 uC, the beads were washed five times with the lysis buffer, twice with cold PBS, and boiled for 6 min in 40 ml of 2 3 SDS loading buffer. Western blotting analysis was performed with anti-AR or anti-FoxA1. Luciferase reporter assay. PC3-AR and HEK293 cells were seeded into 24-well plates in hormone-depleted and phenol-free RMPI 1640 medium and DMEM 1 day before transfection. Transfection was performed according to the manufacturers' recommendations (DOTAP Liposomal Transfection Reagent from Roche or Lipofectamin 2000 from Invitrogen). One day after transfection, these cells were treated with DHT for an additional day. After washing with cold PBS twice, cells were treated with the lysis buffer (Promega) and the Luciferase signal was recorded. Cell proliferation assay. The assay was based on the published protocol 32 . Briefly, LNCaP cells were transfected with control siRNA and FoxA1 siRNA (sequences listed in Methods Summary) and cultured in hormone-depleted medium for 3 days. The cells were treated with different amount of DHT for another day. After the treatment, cells were washed by PBS, fixed by 70% EtOH and stored at 220 uC for at least 2 h. Before analysis, cells were washed with cold PBS, resuspended at the propidium-iodide/Triton X-100 staining solution and incubated at 37 uC for 15 min. After removing cell clumps, stained cells were sorted on a Beckman FASCan, and the percentage of S-phase cells was calculated. ChIP and ChIP-seq analyses. ChIP was as previously described 29 . Briefly, approximately 10 7 treated cells were crosslinked with 1% formaldehyde at room temperature for 15 min. After sonication, the soluble chromatin was incubated with 1-5 mg of antibody. Specific immunocomplexes were precipitated with Protein A/G beads (Sigma-Aldrich). Complexes were washed, DNA extracted and purified by QIAquick Spin columns (Qiagen). Extracted DNA (1 ml from 60 ml) was used for qPCR with the specific PCR primers listed in Supplementary   Fig. 24 , each of which was designed surrounding a specific region of 150-250 base pairs (bp) on target DNA. PCR products were detected with SYBR Green on a MX3000P System (Stratagene) and the percentage of immunoprecipitated chromatin was calculated from DCt relative to immunoglobulin-G control after normalizing against input chromatin. For ChIP-seq, extracted DNA was ligated to specific adaptors followed by deep sequencing in the Illumina GAII system according to the manufacturer's instructions. The first 25 bp for each sequence tag returned by the Illumina Pipeline was aligned to the hg18 assembly (National Center for Biotechnology Information, build 36.1) using Bowtie, allowing up to two mismatches. Only tags uniquely mapped to the genome were used for further analysis. The data were visualized by preparing custom tracks for the University of California, Santa Cruz, genome browser using HOMER 33 (http://biowhat.ucsd. edu/homer). The total number of mappable reads was normalized to 10 7 for each experiment presented in this study. ChIP-seq at nucleosome resolution was performed as previously reported 34 . A summary of ChIP experiments is provided in Supplementary Fig. 25 . Identification of ChIP-seq peaks. The identification of ChIP-seq peaks (bound regions) was performed using HOMER (http://biowhat.ucsd.edu/homer). For transcription factors, peaks were identified by searching locations of high read density using a 200-bp sliding window. Regions of maximal density exceeding a given threshold were called as peaks, and we required adjacent peaks to be at least 500 bp away to avoid redundant detection. Only one tag from each unique position was considered to avoid clonal artefacts from the sequencing. The threshold for the number of tags that determined a valid peak was selected at a false discovery rate of 0.001 determined by peak finding using randomized tag positions in a genome with an effective size of 2 3 10 9 bp. We also required peaks to have at least fourfold more tags (normalized to total count) than input control samples. In addition, we required fourfold more tags relative to the local background region (10 kb) to avoid identifying regions with genomic duplications or non-localized binding.
The peak finding procedure was modified to identify regions harbouring specific histone modifications, as these experiments tend to yield broad areas of enrichment over several hundreds or thousands of base pairs. Seed regions were initially found using a peak size of 500 bp at the false discovery rate of 0.001 to identify enriched loci. Enriched loci found within 1 kb of one another were then merged to yield variable-length regions. Transcription factor peaks and histone modification regions were associated with gene products by identifying the nearest RefSeq TSS. Annotated positions for promoters, exons, introns and other features were based on RefSeq transcripts and repeat annotations from University of California, Santa Cruz. Peaks from separate experiments were considered equivalent/co-bound if their peak centres were located within 200 bp of each other. Read density heat maps were created by first using HOMER to generate read densities and then visualized using Java TreeView (http://jtreeview.sourceforge.net). HOMER for de novo motif discovery and known motif enrichment. Motif discovery was performed using a comparative algorithm similar to those previously described 35 . An in-depth description will be published elsewhere (Benner et al., in preparation). Motif finding for transcription factors was performed on sequence from 6100 bp relative to the peak centre, whereas motif finding for histone modification regions was performed on sequence from 6500 bp relative to the region centre. Briefly, sequences were divided into target and background sets for each application of the algorithm. Background sequences were then selectively weighted to equalize the distributions of G 1 C content in target and background sequences to avoid comparing sequences of different general sequence content. Motifs of length 8, 10, 12, 14, 16 and 18 bp were identified separately by first exhaustively screening all oligonucleotides for enrichment in the target set compared with the background set using the cumulative hypergeometric distribution to score enrichment. Up to three mismatches were allowed in each oligonucleotide sequence to increase the sensitivity of the method. The top 200 oligonucleotides of each length with the lowest P values were then converted into probability matrices and heuristically optimized to maximize hypergeometric enrichment of each motif in the given data set. As optimized motifs were found they were removed from the data set to facilitate the identification of additional motifs in subsequent rounds. HOMER also screens the enrichment of known motifs previously identified through the analysis of published ChIP-ChIP and ChIP-Seq data sets by calculating the known motifs' hypergeometric enrichment in the same set of G 1 C normalized sequences used for de novo analysis. Sequence logos were generated using WebLOGO (http:// weblogo.berkeley.edu). Motif enrichment heatmaps and dendrograms were created by clustering hypergeometric log P values using Cluster (http://bonsai.ims. u-tokyo.ac.jp/,mdehoon/software/cluster/software.htm#ctv) and Java TreeView (http://jtreeview.sourceforge.net). GRO-seq. Global run-on 6 and library preparation for sequencing 30 were done as described. Briefly, four 10-cm plates of confluent LNCaP cells per treatment were washed three times with cold PBS buffer. Cells were then swelled in swelling buffer (10 mM Tris pH 7.5, 2 mM MgCl 2 , 3 mM CaCl 2 ) for 5 min on ice. Harvested cells
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were re-suspended in 1 ml of the lysis buffer (swelling buffer with 0.5% IGEPAL and 10% glycerol) with gentle vortex and brought to 10 ml with the same buffer for extraction of nuclei. Nuclei were washed with 10 ml of lysis buffer and resuspended in 1 ml of freezing buffer (50 mM Tris pH 8.3, 40% glycerol, 5 mM MgCl 2 , 0.1 mM EDTA), pelleted down again and finally re-suspended in 100 ml of freezing buffer.
For run-on assay, re-suspended nuclei were mixed with an equal volume of reaction buffer (10 mM Tris pH 8.0, 5 mM MgCl 2 , 1 mM DTT, 300 mM KCl, 20 units of SUPERase-In, 1% Sarkosyl, 500 mM ATP, GTP and Br-UTP, 2 mM CTP) and incubated for 5 min at 30 uC. Nuclei RNA were extracted with TRIzol LS reagent (Invitogen) according to the manufacturer's instructions. RNA was then re-suspended in 20 ml of DEPC-water and subjected to base hydrolysis by addition of 5 ml of 1 M NaOH and incubated on ice for 40 min. Then, 25 ml of 1 M Tris pH 6.8 was added to neutralize the reaction. RNA was purified through a p-30 RNasefree spin column (BioRad), according to the manufacturer's instructions and treated with 6.7 ml of DNase buffer and 10 ml of RQ1 RNase-free DNase (Promega), and purified again through a p-30 column. A volume of 8.5 ml 10 3 antarctic phosphatase buffer, 1 ml of SUPERase-In and 5 ml of antarctic phosphatase was added to the run-on RNA and treated for 1 h at 37 uC. Before proceeding to immunopurification, RNA was heated to 65 uC for 5 min and kept on ice.
Anti-BrdU argarose beads (Santa Cruz Biotech) were blocked in blocking buffer (0.5 3 SSPE, 1 mM EDTA, 0.05% Tween-20, 0.1% PVP, and 1 mg ml 21 BSA) for 1 h at 4 uC. Heated run-on RNA (,85 ml) was added to 60-ml beads in 500 ml binding buffer (0.5 3 SSPE, 1 mM EDTA, 0.05% Tween-20) and allowed to bind for 1 h at 4 uC with rotation. After binding, beads were washed once in low salt buffer (0.2 3 SSPE, 1 mM EDTA, 0.05% Tween-20), twice in high salt buffer (0.5% SSPE, 1 mM EDTA, 0.05% Tween-20, 150 mM NaCl) and twice in TET buffer (TE pH 7.4, 0.05% Tween-20). BrU-incorporated RNA was eluted with 4 3 125 ml elution buffer (20 mM DTT, 300 mM NaCl, 5 mM Tris pH 7.5, 1 mM EDTA and 0.1% SDS). RNA was then extracted with acidic phenol/chloroform once, chloroform once and precipitated with ethanol overnight. The precipitated RNA was re-suspended in 50 ml reaction (45 ml of DEPC water, 5.2 ml of T4 PNK buffer, 1 ml of SUPERase_In and 1 ml of T4 PNK (NEB)) and incubated at 37 uC for 1 h. The RNA was extracted and precipitated again as above.
Complementary DNA (cDNA) synthesis was performed basically as described 30 with minor modifications. First, RNA fragments were subjected to poly-A tailing reaction in 8.0 ml volume containing 0.8 ml poly-A polymerase buffer, 1 ml 1 mM ATP, 0.5 ml SUPERase-In and 0.75 ml poly-A polymerase (NEB). The reaction was performed for 30 min at 37 uC. Subsequently, reverse transcription was performed using oNTI223 primer (59-pGATCGTCGGACTGTAGAACTCT;CAAGCAGA AGACGGCATACGATTTTTTTTTTTTTTTTTTTTVN-39) where the p indicates 59 phosphorylation, ';' indicates the abasic dSpacer furan and VN indicates degenerate nucleotides.
Tailed RNA (8.0 ml) was mixed with 1 ml dNTP (10 mM each) and 2.5 ml 12.5 mM oNTI223, heated for 3 min at 75 uC and chilled briefly on ice. Then, 0.5 ml SUPERase-In, 3 ml 0.1M DTT, 2 ml 25 mM MgCl 2 , 2 ml 103 reverse transcription buffer and 1 ml superscript III reverse transcriptase (Invitrogen) was added to the tube. The tube was incubated for 30 min at 48 uC. After that, 4 ml of Exonuclease I (Fermentas) was added into the reaction and the tube was incubated for 1 h at 37 uC to eliminate extra oNTI223. Then RNA was eliminated by adding 1.8 ml 1 M NaOH and incubated for 20 min at 98 uC. The reaction was neutralized with 1.8 ml of 1 M HCl. After running on a 10% polyacrylamide TBEurea gel, the extended first-strand cDNA product was excised and recovered by soaking the grinded gel in DNA gel elution buffer (TE with 0.1% Tween-20 and 150 mM NaCl) overnight and then precipitated with ethanol.
Circularization of first-strand cDNA was performed by re-suspending cDNA in 9.5 ml reaction solution (7.5 ml water, 1 ml CircLigase buffer, 0.5 ml 1 mM ATP and 0.5 ml 50 mM MnCl 2 ) and then adding 0.5 ml CircLigase (Epicentre). The reaction went for 1 h at 60 uC and then was heat-inactivated for 20 min at 80 uC. Circularized single-stranded DNA (ssDNA) was relinearized by adding 3.8 ml of 4 3 relinearization supplement (100 mM KCl, 2 mM DTT) followed by 1.5 ml of Ape1 (15u, NEB). The reaction was incubated for 1 h at 37 uC. Relinearized ssDNA was separated in a 10% polyacrylamide TBE-urea gel (Invitrogen) as described above. The relinearized product band was excised (,120-300 bp) and the DNA was recovered as described above.
The ssDNA template was amplified by PCR using the Phusion High-Fidelity enzyme (NEB) according to the manufacturer's instructions. The oligonucleotide primers oNTI200 (59-CAAGCAGAAGACGGCATA-39) and oNTI201 (59-AATG ATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGACG-39) were used to generate DNA for sequencing. PCR was performed with an initial 30-s denaturation at 98 uC, followed by 13 cycles of 10-s denaturation at 98 uC, 15-s annealing at 60 uC and 15-s extension at 72 uC. The PCR product was run on a non-denaturing 8% polyacrylamide TBE gel and recovered as mentioned before.
DNA was then sequenced on the Illumina Genome Analyser II according to the manufacturer's instructions with small RNA sequencing primer 59-CGACAGG TTCAGAGTTCTACAGTCCGACGATC-39. De novo identification of GRO-Seq transcripts. To identify transcription units in an unbiased manner, GRO-Seq read densities were analysed to classify genomic regions into contiguous transcripts using HOMER. GRO-Seq read densities were initially normalized using the GC content of individual reads to remove any systematic bias introduced by overall GC content variation between read libraries. To maximize read depth for transcript identification, all GRO-Seq libraries were merged to perform the initial transcript discovery, and later considered separately to identify regulated transcripts. For each strand of each chromosome, GRO-Seq read densities were calculated using a sliding window of 250 bp. Regions for which GRO-Seq reads could not be uniquely mapped (that is, repeats) were first identified and then read densities in these regions were estimated using upstream read densities from mappable regions to avoid ending predicted transcripts prematurely. Transcript initiation sites were identified as regions where the GRO-Seq read density increased threefold relative to the previous 1 kb region. Transcript termination sites were defined by either a reduction in reads below 10% of the start of the transcript or when another transcript's start site occurred on the same strand. Single spikes in read density covering a span less than 250 bp were considered artefacts and discarded. Identified transcripts were strand-specifically compared with RefSeq transcripts by looking for overlap in the transcribed region. Transcripts were defined as putative eRNAs if their TSS was located distal to
